EISAI TO RECEIVE JAPAN MARKETING AUTHORIZATION HOLDER LICENSE FROM NOBELPHARMA FOR ANTINEOPLASTIC AGENT GLIADEL® 7.7 mg IMPLANT

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that it will receive the Marketing Authorization Holder (MAH) license for the antineoplastic agent Gliadel® 7.7 mg Implant (carmustine, “Gliadel”) in Japan from Nobelpharma Co., Ltd. (Headquarters: Tokyo, President & CEO: Jin Shiomura, “Nobelpharma”), effective December 2.

In Japan, marketing authorization for Gliadel was first received in September 2012 by Nobelpharma after it conducted clinical trials of the agent. Eisai is responsible for domestic sales and distribution of Gliadel under an existing agreement with Nobelpharma and is also co-promoting the agent based on this collaboration, but has decided to act on a licensing option provided in the same agreement that allows Eisai to receive the current Japan MAH license for Gliadel from Nobelpharma. Following the transfer, both companies will continue to promote Gliadel domestically, but with Eisai also responsible for the marketing of the agent in Japan, including responding to the needs of healthcare professionals and ensuring and

[Notes to editors]

1. About Gliadel® 7.7 mg Implant

Gliadel 7.7 mg Implant is the only sustained-release formulation approved for intracranial implantation in Japan. Each wafer contains the nitrosourea alkylating agent carmustine distributed in a biodegradable polymer matrix. Implanting the agent into the brain following surgical removal of malignant glioma allows for direct delivery of chemotherapy to the tumor site, allowing the agent to be used prior to init®